As competition heats up, Novo Nordisk’s share price declines

Original Article by Liesl Peyper | Moneyweb | 24 October 2024

Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

Novo Nordisk’s share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt

Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.

Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.